virtual medicine

with @vintweeta @pbcancerdoc @sumitshahmd @omnivorousread

Coronavirus is now disrupting the entire health care system, not just because of the burden of dealing with the actual disease itself, but because of everything else that's had to grind to a halt. One of the areas where we really worry about things coming to a total stop like that is, of course, cancer treatment, which can often feel like a race against the clock even under the best conditions.

In this episode, Dr. Bobby Green, MD (Community Oncologist and Chief Medical Officer, Flatiron Health) and Dr. Sumit Shah (Oncologist and Head of Digital Health, Stanford Cancer Center) join a16z's Vineeta Agarwala (physician and general partner) and Hanne Tidnam to talk about what is happening to oncology during the outbreak—how treatment is affected; what kind of clinical decisions oncologists and patients are having to make, and how they're making them; the tech tools that specialists are using, and how they could improve; and what happens to oncology as a whole when it's forced to go virtual.

We’re at a moment where we are now seeing medicine go virtual faster, and at a scale that it has never done before. In this conversation,  a16z bio general partners Vijay Pande and Julie Yoo, who come from the worlds of bio, technology and care delivery,  talk with Hanne Tidnam all about what exactly virtual care and “telemedicine” is... and what it isn’t; what it works well for, what doesn’t (yet), and where there’s potential; and finally, the current pain points (including regulation), and what we’ll learn from this current moment for the next generation of virtual medicine tools.